The estimated Net Worth of Albert Robichaud is at least $19.9 Million dollars as of 9 December 2019. Albert Robichaud owns over 25,000 units of Sage Therapeutics Inc stock worth over $1,021,636 and over the last 10 years he sold SAGE stock worth over $15,170,200. In addition, he makes $3,667,260 as Chief Scientific Officer at Sage Therapeutics Inc.
Albert has made over 10 trades of the Sage Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of SAGE stock worth $1,604,000 on 9 December 2019.
The largest trade he's ever made was selling 60,000 units of Sage Therapeutics Inc stock on 14 December 2017 worth over $9,565,800. On average, Albert trades about 7,510 units every 70 days since 2014. As of 9 December 2019 he still owns at least 136,400 units of Sage Therapeutics Inc stock.
You can see the complete history of Albert Robichaud stock trades at the bottom of the page.
Dr. Albert J. Robichaud Ph.D. serves as Chief Scientific Officer of the Company. From 2010 to 2011, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck, Inc., where he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synaptic transmission and neuroinflammation. From 2002 to 2010, Dr. Robichaud was Senior Director and Head of the Neuroscience Discovery Chemistry department of Wyeth Research. During his tenure there, his group successfully delivered more than 15 drug candidates into clinical development in a broad range of neuroscience indications. Dr. Robichaud has co-authored more than 135 manuscripts and abstracts, and is a co-inventor on 70 patents and patent applications. Dr. Robichaud earned a B.S. in chemistry from Rensselaer Polytechnic Institute, a Ph.D. in organic chemistry from the University of California, Irvine and was an American Chemical Society postdoctoral fellow at Colorado State University.
As the Chief Scientific Officer of Sage Therapeutics Inc, the total compensation of Albert Robichaud at Sage Therapeutics Inc is $3,667,260. There are 5 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.
Albert Robichaud is 59, he's been the Chief Scientific Officer of Sage Therapeutics Inc since 2011. There are 4 older and 10 younger executives at Sage Therapeutics Inc. The oldest executive at Sage Therapeutics Inc is Dr. Jeffrey M. Jonas, 68, who is the Chief Innovation Officer, Chair of the Science & Technology Forum and Director.
Albert's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.
Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen, and Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
Sage Therapeutics Inc executives and other stock owners filed with the SEC include: